Chronic Lymphocytic Leukemia
Conditions
Keywords
Chronic Lymphocytic Leukemia, CLL, disease registry, Connect™
Brief summary
The purpose of the Connect™ Chronic Lymphocytic Leukemia (CLL) Disease Registry is to explore the history and real world management of patients diagnosed with CLL, provide insight into the management of CLL, and evaluate the effectiveness of first, second and subsequent therapeutic strategies employed in both the community and academic settings.
Interventions
None listed
Sponsors
Celgene
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis with CLL * Clinical decision made to initiate first-line therapy, second-line therapy or subsequent line of therapy prior to enrollment into the ConnectTM CLL registry, but within 2 months of enrollment * Age≥18 years * Willing and able to provide signed informed consent * Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel
Exclusion criteria
* Participation in a clinical study in which study treatment is blinded * Patient condition is considered terminal (i.e.\<6 months to live)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identify and summarize patterns in therapeutic regimens and patient outcomes | up to 8 years | The primary objective is to 1) describe practice patterns of first line therapy regimens and subsequent therapeutic strategies in patients initiated on therapy for CLL, as well as initiated on second line and subsequent therapies, in the community and academic setting (2) Provide insight into therapeutic regimens and therapy sequence in clinical practice as they relate to clinical outcomes in patients initiated on first-line, second-line or subsequent therapies for CLL. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Summarize Effectiveness of Treatment Regimens | up to 8 years | Describe any differences in effectiveness associated with treatment regimens, including first-line regimens and subsequent therapeutic strategies in patients actively treated for CLL |
| Health Related Quality of Life Measures Related to Therapeutic Regimens | up to 8 years | Describe the health-related quality of life of patients actively treated for CLL, and to explore the association of HRQoL with therapeutic regimens, sequences and clinical outcomes. |
Countries
United States
Outcome results
None listed